April 1, 1992Circulation
Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II.
Why the study?
What are the clinical predictors of early morbidity and mortality after thrombolytic therapy for acute myocardial infarction, and how do outcomes compare between invasive and conservative strategies in specific subgroups?
Population
Patients with acute myocardial infarction receiving thrombolytic therapy in the Thrombolysis in Myocardial…
Comparison
Invasive strategy vs Conservative strategy
Design
Cohort
Follow-up
early
Authors
Discussion
Loading...
Member takes
Implication
Caution advised selecting invasive vs conservative strategies in diabetics or prior-AMI patients post-thrombolysis; leaves open need for randomized confirmation.
Structured PICO
What are the clinical predictors of early morbidity and mortality after thrombolytic therapy for acute myocardial infarction, and how do outcomes compare between invasive and conservative strategies in specific subgroups?
P
Population
Patients with acute myocardial infarction receiving thrombolytic therapy in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II
I
Intervention
Invasive strategy (early catheterization and revascularization)
C
Comparator
Conservative strategy
O
Outcome
Early mortality and morbidity (reinfarction)hard clinical
Clinical variables such as cardiogenic shock, prior myocardial infarction, and diabetes can identify subgroups of patients who may benefit differentially from invasive versus conservative management after thrombolysis for acute myocardial infarction.
Cite This Study
Mueller et al. (1992) studied this question.